News
Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced alignment with the United States Food and Drug Administration (FDA) on items ...
The ASX biotech sector's best EOFY performer has come from left field: the local and European focused medicinal cannabis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback